Cite
DeZure AD, Coates EE, Hu Z, et al. An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial. NPJ Vaccines. 2017;2:15doi: 10.1038/s41541-017-0016-6.
DeZure, A. D., Coates, E. E., Hu, Z., Yamshchikov, G. V., Zephir, K. L., Enama, M. E., Plummer, S. H., Gordon, I. J., Kaltovich, F., Andrews, S., McDermott, A., Crank, M. C., Koup, R. A., Schwartz, R. M., Bailer, R. T., Sun, X., Mascola, J. R., Tumpey, T. M., Graham, B. S., & Ledgerwood, J. E. (2017). An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial. NPJ vaccines, 215. https://doi.org/10.1038/s41541-017-0016-6
DeZure, Adam D, et al. "An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial." NPJ vaccines vol. 2 (2017): 15. doi: https://doi.org/10.1038/s41541-017-0016-6
DeZure AD, Coates EE, Hu Z, Yamshchikov GV, Zephir KL, Enama ME, Plummer SH, Gordon IJ, Kaltovich F, Andrews S, McDermott A, Crank MC, Koup RA, Schwartz RM, Bailer RT, Sun X, Mascola JR, Tumpey TM, Graham BS, Ledgerwood JE. An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial. NPJ Vaccines. 2017 Jun 01;2:15. doi: 10.1038/s41541-017-0016-6. eCollection 2017. PMID: 29263871; PMCID: PMC5627236.
Copy
Download .nbib